[조사자료] 글로벌 호흡기 진단 시장 예측 (~2029) :기기, 시약, 소프트웨어

■ 영문 제목 : Respiratory Diagnostics Market by Product & Services (Devices, Reagents, Software), Test (PFT, Peak Flow, Spirometry), OSA, Imaging (X-ray, CT, MRI, PET), Molecular (PCR, DNA Sequencing), Indication (Lung Cancer, Asthma, COPD, TB) - Global Forecast to 2029
	■ 상품코드 : MD4740-23 ■ 조사/발행회사 : MarketsandMarkets ■ 발행일 : 2023년 11월 ■ 페이지수 : 338 ■ 작성언어 : 영문 ■ 보고서 형태 : PDF ■ 납품 방식 : Email (주문후 24시간내 납품) ■ 조사대상 지역 : 세계 ■ 산업 분야 : 의료 기기

■ 판매가격 / 옵션 (부가세 10% 별도)

Single User	USD4,950 ⇒환산￦6,682,500	견적의뢰/주문/질문
Multi User (Five User)	USD6,650 ⇒환산￦8,977,500	견적의뢰/주문/질문
Corporate License	USD8,150 ⇒환산￦11,002,500	견적의뢰/구입/질문

※가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.

"글로벌 호흡기 진단 시장은 2023년 56억 달러에서 2029년 82억 달러에 달할 것으로 예상되며, 예측 기간 동안 연평균 6.6%의 성장률을 기록할 것으로 전망됩니다."호흡기 진단 시장의 성장은 전 세계적으로 증가하는 호흡기 질환의 부담 증가에 대응하는 다양한 요인의 조합에 의해 주도되고 있습니다. 기술 발전, 특히 진단 도구와 영상 진단 기술의 발전으로 호흡기 진단의 정확성과 효율성이 크게 향상되어 COPD, 결핵, 폐암과 같은 질환을 조기에 발견하고 보다 효과적으로 관리할 수 있게 되었습니다. 조기 진단의 중요성에 대한 의료진과 일반인의 인식이 높아지면서 정부 주도의 검진 프로그램과 함께 호흡기 진단 검사에 대한 수요 증가에 기여하고 있습니다. 신종 코로나 바이러스 감염증 팬데믹은 시장에 새로운 국면을 가져왔고, 호흡기 감염증의 신속하고 정확한 진단의 시급성을 강조하고 있습니다. 제품 승인, 라벨링, 품질 표준에 대한 새로운 요구 사항과 같은 규제 변경은 시장 성장을 억제할 수 있습니다.

"기기 및 장치 부문이 가장 큰 점유율을 차지하며 예측 기간 동안 가장 높은 성장률을 보일 것으로 예상됩니다."
이는 영상진단 장비, 폐활량계 및 기타 호흡기 진단 장비와 같은 진단 기술의 지속적인 발전에 기인합니다. 또한, 전 세계적으로 호흡기 질환의 유병률이 증가함에 따라 고급 및 정확한 진단 도구에 대한 수요가 증가하면서 이 부문의 중요성이 커지고 있습니다. 현장 검사 장비 및 휴대용 진단 기기의 혁신은 의료진이 신속하고 정확한 호흡기 평가를 수행 할 수 있도록 지원하여 기기 및 장비 부문의 성장을 더욱 촉진하고 있습니다. 따라서 앞서 언급한 요인들이 호흡기 진단 시장의 성장을 촉진하고 있습니다.

"기계적 검사 분야가 가장 큰 점유율을 차지하며 예측 기간 동안 가장 높은 성장률을 보일 것으로 예상됩니다."
기계적 검사에는 폐활량 및 기류 평가에 중요한 역할을 하는 폐활량계 및 피크 유량계와 같은 진단 도구가 포함됩니다. 호흡기 질환의 유병률 증가와 정확한 진단 및 모니터링의 필요성이 기계적 검사에 대한 수요를 촉진하고 있습니다. 또한 기술 발전은 이러한 검사의 효율성과 정확성을 향상시켜 보급을 더욱 촉진하고 있습니다. 호흡 기능에 대한 정밀하고 포괄적인 기계적 평가에 대한 수요 증가는 호흡기 진단 시장의 성장을 촉진할 것입니다.

"천식 분야가 전 세계 호흡기 진단 시장에서 가장 큰 점유율을 차지할 것으로 예상됩니다."
환경오염물질의 증가, 생활습관의 변화, 유전적 요인 등이 천식 발병률 증가에 기여하고 있으며, 이에 따라 첨단 진단 솔루션의 필요성이 대두되고 있습니다. 천식 분야는 폐기능 검사, 영상진단 기술, 바이오마커 평가 등 다양한 진단 수단을 아우르며 천식 진단과 관리에 대한 포괄적인 접근을 제공합니다. 이 분야는 개인 맞춤형 의료에 초점을 맞춘 지속적인 연구 개발이 이루어지고 있으며, 호흡기 진단 시장의 성장을 주도하고 있습니다.

"병원 및 클리닉 최종 사용자 부문은 세계 호흡기 진단 시장 예측 기간 동안 가장 높은 CAGR로 성장하며 가장 큰 시장 점유율을 유지할 것으로 예상됩니다."
호흡기 질환의 증가는 조기 발견의 중요성에 대한 인식의 증가와 함께 이러한 시설에서 수행되는 진단 절차의 급증으로 이어지고 있습니다. 병원 및 클리닉 부문은 영상 검사, 폐 기능 검사, 분자 진단 등 다양한 진단 도구와 서비스를 포괄하며 호흡기 건강 평가에 대한 포괄적인 접근 방식을 제공합니다. 병원과 클리닉이 질병의 진단, 관리 및 치료에 있어 핵심적인 역할을 하는 의료 현장에서 호흡기 진단 서비스에 대한 수요가 증가함에 따라 이 부문은 호흡기 진단의 진화하는 과제를 해결하는 최전선에 서게 될 것입니다.

"북미는 2023년부터 2029년까지 괄목할 만한 성장세를 보일 것으로 예상됩니다."
호흡기 진단 시장은 북미, 유럽, 아시아 태평양, 중남미, 중동 및 아프리카의 5개 주요 지역 부문으로 구분되며, 2022년까지 아시아 태평양이 예측 기간 동안 가장 높은 연평균 성장률(CAGR)을 기록할 것으로 예상됩니다. 그러나 북미 시장이 세계 시장에서 가장 큰 시장 점유율을 차지하고 있습니다. 북미는 호흡기 진단 시장의 선두 주자로서 예측 기간 동안 가장 큰 시장 점유율을 차지할 것으로 예상됩니다. 이러한 선도적 지위는 잘 구축된 의료 인프라, 높은 호흡기 질환 유병률, 이 지역의 활발한 R&D 활동 등 여러 가지 요인에 기인합니다. 첨단 진단 기술이 발달하고, 질병의 조기 발견과 조기 관리에 중점을 두고 있는 것도 이 지역의 우위에 기여하고 있습니다. 또한, 의료비 증가, 노인 인구 증가, 호흡기 질환에 대한 인식이 높아지면서 시장 성장을 더욱 촉진하고 있습니다.

공급측의 1차 인터뷰 분석은 다음과 같습니다.
- 기업 유형별: Tier 1 - 35%, Tier 2 - 40%, Tier 3 - 25%.
- 직급별: C레벨 - 30%, 이사급 - 23%, 기타 - 47%.
- 지역별: 북미 - 35%, 유럽 - 20%, 아시아 태평양 - 25%, 중남미 - 13%, 중동 및 아프리카 - 7%.

호흡기 진단 시장의 주요 기업으로는 Koninklijke Philips N.V. (네덜란드), BD (미국), Abbott (미국), Thermo Fisher Scientific Inc. Laboratories, Inc. (미국), BioMérieux (프랑스), Revvity, Inc. SDI Diagnostics (미국), ResMed Inc. (미국), Siemens Healthcare GmbH (독일), Cosmed (이탈리아), Hologic, Inc. Visby Medical, Inc (미국), Briota Technologies Private Limited (인도), Bird Healthcare (호주), Löwenstein Medical Technology (독일), ProAxsis (북아일랜드), Cosmed (이탈리아), Hologic, Inc. ProAxsis (북아일랜드), ndd Medical Technologies (미국), Compumedics Limited (호주) 등이 포함됩니다.

조사 범위:
본 보고서는 호흡기 진단 시장을 제품 및 서비스, 검사 유형, 적응증 질환, 최종 사용자, 지역별로 조사하고 있습니다. 또한 시장 성장에 영향을 미치는 요인(촉진요인, 저해요인, 기회, 과제 등)을 조사하고 있습니다. 시장의 기회와 과제를 분석하여 시장 리더를 위한 경쟁 환경에 대한 자세한 정보를 제공합니다. 또한, 개별 성장 동향과 관련하여 마이크로 시장을 분석하고, 5개 주요 지역과 각 국가별로 시장 부문의 수익을 예측합니다.

보고서 구매 이유:
이 보고서는 기존 기업뿐만 아니라 신규 진입자 및 소규모 기업에게도 시장 동향을 파악하는 데 도움이 될 수 있습니다. 본 보고서를 구매하는 기업은 아래 5가지 전략 중 하나 또는 조합하여 사용할 수 있습니다.

본 보고서에서는 다음과 같은 내용을 다루고 있습니다.
- 주요 촉진 요인(호흡기 질환 유병률 증가, 조산율 증가, 호흡기에 영향을 미치는 감염성 질환의 유행 증가, 수면 장애 인구 증가, 의료 기기 기술 발전을 위한 R&D 투자 증가), 저해요인 분석(호흡기 진단 약품에 대한 불리한 상환 시나리오), 기회 (아시아 태평양 및 중남미 호흡기 진단 시장의 높은 성장 기회, POC 진단약의 개선, 치료되지 않은 수면무호흡증후군의 부작용에 대한 인식 증가), 도전 과제(호흡기 질환에 대한 낮은 인식과 진단 부족)에 대한 분석을 제공합니다.
- 제품 개발/혁신: 호흡기 진단 시장의 미래 기술, R&D 활동, 제품 출시에 대한 자세한 인사이트를 제공합니다.
- 시장 개발: 유망한 신흥 시장에 대한 포괄적인 정보를 제공합니다. 이 보고서는 다양한 유형의 호흡기 진단 시장을 지역별로 분석합니다.
- 시장 다각화: 호흡기 진단 시장의 제품, 미개척 지역, 최근 개발 및 투자에 대한 정보를 제공합니다.
- 경쟁 평가: 호흡기 진단 시장의 주요 기업들의 시장 점유율, 전략, 제품, 유통망, 제조 능력에 대한 상세한 평가를 제공합니다.

■ 보고서 개요

1. 소개
2. 조사 방법
3. 개요
4. 프리미엄 인사이트
5. 시장 개요
6. 세계의 호흡기 진단 시장 규모 : 제품 및 서비스별
7. 세계의 호흡기 진단 시장 규모 : 검사 유형별
8. 세계의 호흡기 진단 시장 규모 : 질환별
9. 세계의 호흡기 진단 시장 규모 : 최종 용도별
10. 세계의 호흡기 진단 시장 규모 : 지역별
11. 경쟁 현황
12. 기업 정보
13. 부록

■ 보고서 목차

1 INTRODUCTION 42
1.1 STUDY OBJECTIVES 42
1.2 MARKET DEFINITION 43
1.3 INCLUSIONS & EXCLUSIONS 43
1.4 MARKET SCOPE 44
1.4.1 MARKETS COVERED 44
1.4.2 REGIONS COVERED 45
1.4.3 YEARS CONSIDERED 45
1.4.4 CURRENCY CONSIDERED 46
1.5 STAKEHOLDERS 46
1.6 SUMMARY OF CHANGES 46
1.6.1 RECESSION IMPACT 47
2 RESEARCH METHODOLOGY 48
2.1 RESEARCH DATA 48
FIGURE 1 RESEARCH DESIGN 48
2.1.1 SECONDARY DATA 49
2.1.1.1 Key data from secondary sources 50
2.1.2 PRIMARY DATA 50
FIGURE 2 PRIMARY SOURCES 50
2.1.2.1 Key industry insights 51
2.1.2.2 Key data from primary sources 52
2.1.2.3 Breakdown of primary interviews 52
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 52
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY END USER, DESIGNATION, AND REGION 53
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 53
2.2 MARKET SIZE ESTIMATION 54
FIGURE 6 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 54
FIGURE 7 REVENUE SHARE ANALYSIS ILLUSTRATION: KONINKLIJKE PHILIPS N.V. 55
FIGURE 8 SUPPLY-SIDE ANALYSIS: RESPIRATORY DIAGNOSTICS MARKET (2022) 55
FIGURE 9 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 57
FIGURE 10 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 58
FIGURE 11 TOP-DOWN APPROACH 59
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 60
FIGURE 12 MARKET DATA TRIANGULATION METHODOLOGY 60
2.4 MARKET SHARE ESTIMATION 61
2.5 STUDY ASSUMPTIONS 61
2.6 RESEARCH LIMITATIONS 62
2.6.1 METHODOLOGY-RELATED LIMITATIONS 62
2.6.2 SCOPE-RELATED LIMITATIONS 62
2.7 RISK ASSESSMENT 62
TABLE 1 RISK ASSESSMENT: RESPIRATORY DIAGNOSTICS MARKET 62
2.8 IMPACT OF RECESSION ON RESPIRATORY DIAGNOSTICS MARKET 62
3 EXECUTIVE SUMMARY 63
FIGURE 13 RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2023 VS. 2029 (USD MILLION) 63
FIGURE 14 RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2023 VS. 2029 (USD MILLION) 64
FIGURE 15 RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2023 VS. 2029 (USD MILLION) 64
FIGURE 16 RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2023 VS. 2029 (USD MILLION) 65
FIGURE 17 GEOGRAPHICAL SNAPSHOT OF RESPIRATORY DIAGNOSTICS MARKET 66
4 PREMIUM INSIGHTS 67
4.1 RESPIRATORY DIAGNOSTICS MARKET OVERVIEW 67
FIGURE 18 TECHNOLOGICAL ADVANCEMENTS AND GROWTH IN GERIATRIC POPULATION TO DRIVE MARKET 67
4.2 GEOGRAPHICAL GROWTH OPPORTUNITIES: RESPIRATORY DIAGNOSTICS MARKET 68
FIGURE 19 NORTH AMERICA COMMANDED LARGEST MARKET SHARE IN 2022 68
4.3 REGIONAL MIX: RESPIRATORY DIAGNOSTICS MARKET 68
FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 68
4.4 DEVELOPED VS. EMERGING ECONOMIES: RESPIRATORY DIAGNOSTICS MARKET, 2023 VS. 2029 (USD MILLION) 69
FIGURE 21 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH DURING STUDY PERIOD 69
5 MARKET OVERVIEW 70
5.1 INTRODUCTION 70
5.2 MARKET DYNAMICS 70
FIGURE 22 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES: RESPIRATORY DIAGNOSTICS MARKET 70
5.2.1 DRIVERS 71
5.2.1.1 Rising prevalence of respiratory diseases 71
5.2.1.1.1 Growth in global geriatric population 72
FIGURE 23 GLOBAL GERIATRIC POPULATION, BY REGION 72
5.2.1.1.2 Urbanization and growing pollution levels 72
FIGURE 24 PERCENTAGE OF DEATHS CAUSED BY HOUSEHOLD AND AMBIENT AIR POLLUTION, BY DISEASE (APPROXIMATELY, EVERY YEAR) 73
5.2.1.1.3 Rising prevalence of tobacco smoking 73
TABLE 2 PREVALENCE OF LIFESTYLE DISEASES AND RELATED DEATHS 73
5.2.1.1.4 Changing lifestyle, obesity, and physical inactivity 74
5.2.1.2 Increasing rate of preterm births 74
TABLE 3 TOP 10 COUNTRIES WITH HIGHEST NUMBER OF PRETERM BIRTHS, 2020 74
FIGURE 25 PRETERM BIRTH BY GESTATIONAL AGE AND REGION, 2020 75
5.2.1.3 Increasing outbreaks of infectious diseases affecting respiratory system 75
5.2.1.4 Growing population with sleep disorders 75
5.2.1.5 Rising R&D investments for technologically advanced medical devices 76
5.2.2 RESTRAINTS 76
5.2.2.1 Unfavorable reimbursement policies 76
5.2.2.2 Availability of low-cost products from local manufacturers 77
5.2.3 OPPORTUNITIES 77
5.2.3.1 Increased market growth in Asia Pacific and Latin America 77
5.2.3.2 Improving POC diagnostics 77
5.2.3.3 Increasing ill effects of untreated sleep apnea 78
TABLE 4 INITIATIVES TO PROMOTE AWARENESS ABOUT ILL EFFECTS OF UNTREATED SLEEP APNEA 78
5.2.4 CHALLENGES 79
5.2.4.1 Low awareness and lack of diagnosis of respiratory diseases 79
5.3 INDUSTRY TRENDS 80
5.3.1 RISING DEMAND FOR POINT-OF-CARE DIAGNOSTIC DEVICES 80
5.3.2 FOCUS OF MARKET PLAYERS ON GEOGRAPHICAL EXPANSIONS 80
5.3.3 INCREASING NUMBER OF REAGENT RENTAL AGREEMENTS 80
5.4 SUPPLY CHAIN ANALYSIS 81
FIGURE 26 SUPPLY CHAIN ANALYSIS: RESPIRATORY DIAGNOSTICS MARKET 82
5.5 TARIFF AND REGULATORY ANALYSIS 82
5.5.1 REGULATORY ANALYSIS 82
5.5.1.1 North America 82
5.5.1.1.1 US 82
TABLE 5 US: CLASSIFICATION OF MEDICAL EQUIPMENT 82
TABLE 6 US: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 83
5.5.1.1.2 Canada 83
TABLE 7 CANADA: LEVEL OF RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 83
5.5.1.2 Europe 84
TABLE 8 EUROPE: LEVEL OF RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 84
5.5.1.3 Asia Pacific 84
5.5.1.3.1 Japan 84
TABLE 9 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 85
5.5.1.3.2 China 85
TABLE 10 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 85
5.5.1.3.3 India 86
5.5.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86
5.5.2.1 North America 86
TABLE 11 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86
5.5.2.2 Europe 87
TABLE 12 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87
5.5.2.3 Rest of the World 88
TABLE 13 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88
5.6 ECOSYSTEM MARKET MAP 89
FIGURE 27 ECOSYSTEM MARKET MAP: RESPIRATORY DIAGNOSTICS MARKET 89
5.7 VALUE CHAIN ANALYSIS 90
FIGURE 28 VALUE CHAIN ANALYSIS: RESPIRATORY DIAGNOSTICS MARKET 91
5.8 TECHNOLOGY ANALYSIS 91
5.8.1 KEY TECHNOLOGIES 91
5.8.1.1 Digitalization of diagnostic tests 91
5.8.2 ADJACENT TECHNOLOGIES 92
5.8.2.1 Rapid respiratory diagnostic kits 92
5.8.3 COMPLEMENTARY TECHNOLOGIES 93
5.9 PATENT ANALYSIS 94
5.9.1 PATENT PUBLICATION TRENDS 94
FIGURE 29 PATENT PUBLICATION TRENDS, 2013–2023 94
5.9.2 JURISDICTION AND TOP APPLICANT ANALYSIS 94
FIGURE 30 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS) FOR RESPIRATORY DIAGNOSTIC PATENTS (JANUARY 2013–NOVEMBER 2023) 95
FIGURE 31 TOP APPLICANT COUNTRIES/REGIONS FOR RESPIRATORY DIAGNOSTIC PATENTS (JANUARY 2013–NOVEMBER 2023) 95
5.10 TRADE ANALYSIS 96
TABLE 14 TOP EXPORTERS OF RESPIRATORY DIAGNOSTICS DEVICES, 2022 (USD MILLION) 96
5.11 CASE STUDY ANALYSIS 97
TABLE 15 MONITORING OF COPD PATIENTS AT HOME 97
TABLE 16 REPLACEMENT PATTERN OF VENTILATORS IN DEVELOPED ECONOMIES VS. EMERGING ECONOMIES 97
TABLE 17 VOLUME DATA OF VENTILATORS, ICU VENTILATORS, PORTABLE VENTILATORS, PAP DEVICES, CPAP DEVICES, BIPAP DEVICES, AND SPIROMETERS 98
5.12 PORTER’S FIVE FORCES ANALYSIS 98
TABLE 18 PORTER’S FIVE FORCES ANALYSIS 98
5.12.1 THREAT OF NEW ENTRANTS 99
5.12.2 THREAT OF SUBSTITUTES 99
5.12.3 BARGAINING POWER OF SUPPLIERS 100
5.12.4 BARGAINING POWER OF BUYERS 100
5.12.5 INTENSITY OF COMPETITIVE RIVALRY 100
5.13 KEY CONFERENCES & EVENTS 100
TABLE 19 LIST OF KEY CONFERENCES & EVENTS IN 2023–2024 100
5.14 KEY STAKEHOLDERS & BUYING CRITERIA 101
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 101
FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR RESPIRATORY DIAGNOSTIC DEVICES 101
TABLE 20 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS 102
5.14.2 BUYING CRITERIA 102
FIGURE 33 KEY BUYING CRITERIA FOR RESPIRATORY DIAGNOSTIC DEVICES 102
TABLE 21 KEY BUYING CRITERIA FOR RESPIRATORY DIAGNOSTIC DEVICES 102
5.15 PRICING ANALYSIS 103
TABLE 22 AVERAGE SELLING PRICE OF RESPIRATORY DIAGNOSTIC DEVICES, BY PRODUCT TYPE (USD) 103
5.15.1 AVERAGE SELLING PRICE TREND, BY REGION 103
5.16 ADJACENT MARKETS 103
FIGURE 34 ADJACENT MARKETS OF RESPIRATORY DIAGNOSTICS MARKET 103
5.17 UNMET NEEDS IN RESPIRATORY DIAGNOSTIC DEVICES 104
5.18 USE OF ARTIFICIAL INTELLIGENCE IN RESPIRATORY DIAGNOSTICS MARKET 105
TABLE 23 USE OF ARTIFICIAL INTELLIGENCE IN RESPIRATORY DIAGNOSTICS MARKET 105
5.18.1 USE OF BIG DATA AND ARTIFICIAL INTELLIGENCE IN HEALTHCARE 105
5.19 REIMBURSEMENT SCENARIO ANALYSIS 106
TABLE 24 REIMBURSEMENT SCENARIO: RESPIRATORY DIAGNOSTICS MARKET 106
6 RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE 108
6.1 INTRODUCTION 109
TABLE 25 RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION) 109
6.2 INSTRUMENTS AND DEVICES 109
6.2.1 INCREASING PREVALENCE OF RESPIRATORY DISEASES TO DRIVE MARKET 109
TABLE 26 RESPIRATORY DIAGNOSTICS MARKET FOR INSTRUMENTS AND DEVICES, BY COUNTRY, 2021–2029 (USD MILLION) 110
6.3 ASSAYS AND REAGENTS 110
6.3.1 RISING DEMAND FOR RESPIRATORY DIAGNOSTIC TEST KITS TO DRIVE MARKET 110
TABLE 27 RESPIRATORY DIAGNOSTICS MARKET FOR ASSAYS AND REAGENTS, BY COUNTRY, 2021–2029 (USD MILLION) 111
6.4 SERVICES AND SOFTWARE 111
6.4.1 INTRODUCTION TO ADVANCED AND AUTOMATED TECHNOLOGIES TO DRIVE MARKET 111
TABLE 28 RESPIRATORY DIAGNOSTICS MARKET FOR SERVICES & SOFTWARE, BY COUNTRY, 2021–2029 (USD MILLION) 112

7 RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE 113
7.1 INTRODUCTION 114
TABLE 29 RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION) 114
7.2 MECHANICAL TESTS 114
TABLE 30 RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY COUNTRY, 2021–2029 (USD MILLION) 115
TABLE 31 RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION) 115
7.2.1 PULMONARY FUNCTION TESTS 116
TABLE 32 PULMONARY FUNCTION TESTS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 116
TABLE 33 PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION) 117
7.2.2 SPIROMETRY 117
7.2.2.1 Spirometry to dominate pulmonary function tests segment during forecast period 117
TABLE 34 SPIROMETRY TESTS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 118
7.2.3 PEAK FLOW TESTS 118
7.2.3.1 Precise measurements from peak flow tests to help focus on effective treatment plans 118
TABLE 35 PEAK FLOW TESTS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 119
7.2.4 OBSTRUCTIVE SLEEP APNEA TESTS 119
7.2.4.1 Increased focus on diagnosis of sleep apnea at early stages to drive segment 119
TABLE 36 OBSTRUCTIVE SLEEP APNEA TESTS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 120
7.2.5 OTHER MECHANICAL TESTS 120
TABLE 37 OTHER MECHANICAL TESTS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 121
7.3 IMAGING TESTS 121
TABLE 38 RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY COUNTRY, 2021–2029 (USD MILLION) 122
TABLE 39 RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION) 122
7.3.1 X-RAY 123
7.3.1.1 Increased investments in advanced radiographic technologies for superior lung imaging to drive segment 123
TABLE 40 X-RAY MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 123
7.3.2 COMPUTED TOMOGRAPHY 123
7.3.2.1 Growing focus on manufacturing high-resolution CT imaging for comprehensive respiratory assessments to drive segment 123
TABLE 41 COMPUTED TOMOGRAPHY MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 124

7.3.3 MAGNETIC RESONANCE IMAGING 124
7.3.3.1 Rising investments in AI-enhanced MRI analysis for precise respiratory assessment to drive segment 124
TABLE 42 MAGNETIC RESONANCE IMAGING MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 125
7.3.4 POSITRON EMISSION TOMOGRAPHY 125
7.3.4.1 Increased focus on effective treatment and management of lung cancer to drive segment 125
TABLE 43 POSITRON EMISSION TOMOGRAPHY MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 126
7.3.5 OTHER IMAGING TESTS 126
TABLE 44 OTHER IMAGING TESTS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 127
7.4 TRADITIONAL DIAGNOSTIC TESTS 127
TABLE 45 RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY COUNTRY, 2021–2029 (USD MILLION) 128
TABLE 46 RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION) 128
7.4.1 IMMUNODIAGNOSTICS 129
7.4.1.1 Increased focus on rapid disease diagnosis to drive segment 129
TABLE 47 IMMUNODIAGNOSTICS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 129
7.4.2 BIOCHEMICAL CHARACTERIZATION 130
7.4.2.1 Rising number of collaborations among biochemical laboratories for developing advanced diagnostics to drive segment 130
TABLE 48 BIOCHEMICAL CHARACTERIZATION MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 130
7.4.3 MICROSCOPY 131
7.4.3.1 Lack of sensitivity toward emerging diseases and potential virus bioterrorism to limit market 131
TABLE 49 MICROSCOPY MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 131
7.5 MOLECULAR DIAGNOSTIC TESTS 132
TABLE 50 RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTIC TESTS, BY COUNTRY, 2021–2029 (USD MILLION) 132
TABLE 51 RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION) 133
7.5.1 PCR 133
7.5.1.1 Development of portable, real-time PCR machines and assays to drive segment 133
TABLE 52 PCR MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 134
7.5.2 NUCLEIC ACID AMPLIFICATION 134
7.5.2.1 Growing focus on automated nucleic acid amplification processes to drive segment 134
TABLE 53 NUCLEIC ACID AMPLIFICATION MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 135
7.5.3 IN SITU HYBRIDIZATION 135
7.5.3.1 Increased adoption of automated technologies for streamlined respiratory testing to drive segment 135
TABLE 54 IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 136
7.5.4 DNA SEQUENCING AND NEXT-GENERATION SEQUENCING 136
7.5.4.1 Rising number of research activities on sequencing-based biomarkers to drive segment 136
TABLE 55 DNA SEQUENCING AND NEXT GENERATION SEQUENCING MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 137
7.5.5 MICROARRAYS 137
7.5.5.1 Easy and effective detection of genetic signatures across multiple genes to drive segment 137
TABLE 56 MICROARRAYS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 138
7.5.6 OTHER MOLECULAR DIAGNOSTIC TESTS 138
TABLE 57 OTHER MOLECULAR DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 139
8 RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION 140
8.1 INTRODUCTION 141
TABLE 58 RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION) 141
8.2 TUBERCULOSIS 141
8.2.1 INCREASING EARLY SCREENING PROGRAMS AND FUNDS BY GOVERNMENT TO DRIVE MARKET 141
TABLE 59 RESPIRATORY DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2021–2029 (USD MILLION) 142
8.3 ASTHMA 142
8.3.1 INCREASING AIR POLLUTION AND GROWING USE OF TOBACCO-BASED PRODUCTS TO DRIVE MARKET 142
TABLE 60 RESPIRATORY DIAGNOSTICS MARKET FOR ASTHMA, BY COUNTRY, 2021–2029 (USD MILLION) 143
8.4 LUNG CANCER 143
8.4.1 INCREASING NUMBER OF TOBACCO CONSUMERS TO DRIVE MARKET 143
TABLE 61 RESPIRATORY DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2021–2029 (USD MILLION) 144
8.5 CHRONIC OBSTRUCTIVE PULMONARY DISEASE 144
8.5.1 INCREASED INVESTMENT IN RESEARCH GRANTS FOR NOVEL BIOMARKERS AND DIAGNOSTIC TECHNOLOGIES TO DRIVE MARKET 144
TABLE 62 RESPIRATORY DIAGNOSTICS MARKET FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY COUNTRY, 2021–2029 (USD MILLION) 145
8.6 OTHER RESPIRATORY DISEASES 145
TABLE 63 RESPIRATORY DIAGNOSTICS MARKET FOR OTHER RESPIRATORY DISEASES, BY COUNTRY, 2021–2029 (USD MILLION) 146
9 RESPIRATORY DIAGNOSTICS MARKET, BY END USER 147
9.1 INTRODUCTION 148
TABLE 64 RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 148
9.2 HOSPITALS AND CLINICS 148
9.2.1 HOSPITALS AND CLINICS SEGMENT TO COMMAND LARGEST MARKET SHARE DURING STUDY PERIOD 148
TABLE 65 RESPIRATORY DIAGNOSTICS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2029 (USD MILLION) 149
9.3 DIAGNOSTIC LABORATORIES 149
9.3.1 EASY AND AFFORDABLE TESTING PROCESSES WITH TIMELY AND ACCURATE RESULTS TO DRIVE MARKET 149
TABLE 66 RESPIRATORY DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2021–2029 (USD MILLION) 150
9.4 OTHER END USERS 150
TABLE 67 RESPIRATORY DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2029 (USD MILLION) 151
10 RESPIRATORY DIAGNOSTICS MARKET, BY REGION 152
10.1 INTRODUCTION 153
FIGURE 35 RESPIRATORY DIAGNOSTICS MARKET REGIONAL SNAPSHOT 153
TABLE 68 RESPIRATORY DIAGNOSTICS MARKET, BY REGION, 2021–2029 (USD MILLION) 154
10.2 NORTH AMERICA 155
FIGURE 36 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET SNAPSHOT 155
TABLE 69 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 156
TABLE 70 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION) 156
TABLE 71 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION) 156
TABLE 72 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION) 157
TABLE 73 NORTH AMERICA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION) 157
TABLE 74 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION) 157
TABLE 75 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION) 158
TABLE 76 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION) 158
TABLE 77 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION) 159
TABLE 78 NORTH AMERICA RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 159
10.2.1 NORTH AMERICA: RECESSION IMPACT 159
10.2.2 US 160
10.2.2.1 US to dominate North American respiratory diagnostics market during forecast period 160
TABLE 79 US: KEY MACROINDICATORS 160
TABLE 80 US: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION) 161
TABLE 81 US: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION) 161
TABLE 82 US: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION) 161
TABLE 83 US: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION) 162
TABLE 84 US: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION) 162
TABLE 85 US: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION) 162
TABLE 86 US: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION) 163
TABLE 87 US: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION) 163
TABLE 88 US: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 164
10.2.3 CANADA 164
10.2.3.1 Growing geriatric population and increasing awareness about early diagnosis of respiratory diseases to drive market 164
TABLE 89 CANADA: COPD AND ASTHMA STATISTICS (2019 VS. 2020) 164
TABLE 90 CANADA: KEY MACROINDICATORS 165
TABLE 91 CANADA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION) 165
TABLE 92 CANADA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION) 166
TABLE 93 CANADA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION) 166
TABLE 94 CANADA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION) 166
TABLE 95 CANADA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION) 167
TABLE 96 CANADA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION) 167
TABLE 97 CANADA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION) 168
TABLE 98 CANADA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION) 168
TABLE 99 CANADA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 169
10.3 EUROPE 169
TABLE 100 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 169
TABLE 101 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION) 170
TABLE 102 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION) 170
TABLE 103 EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION) 170
TABLE 104 EUROPE: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION) 171
TABLE 105 EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION) 171
TABLE 106 EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION) 171
TABLE 107 EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION) 172
TABLE 108 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION) 172
TABLE 109 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 173
10.3.1 EUROPE: RECESSION IMPACT 173
10.3.2 GERMANY 173
10.3.2.1 Increasing public healthcare expenditure to drive market 173
TABLE 110 GERMANY: KEY MACROINDICATORS 174
TABLE 111 GERMANY: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION) 174
TABLE 112 GERMANY: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION) 174
TABLE 113 GERMANY: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION) 175
TABLE 114 GERMANY: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION) 175
TABLE 115 GERMANY: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION) 175
TABLE 116 GERMANY: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION) 176
TABLE 117 GERMANY: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION) 176
TABLE 118 GERMANY: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION) 177
TABLE 119 GERMANY: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 177
10.3.3 FRANCE 177
10.3.3.1 Increasing prevalence of COPD and growing geriatric population to drive market 177
TABLE 120 FRANCE: KEY MACROINDICATORS 178
TABLE 121 FRANCE: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION) 178
TABLE 122 FRANCE: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION) 178
TABLE 123 FRANCE: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION) 179
TABLE 124 FRANCE: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION) 179
TABLE 125 FRANCE: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION) 179
TABLE 126 FRANCE: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION) 180
TABLE 127 FRANCE: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION) 180
TABLE 128 FRANCE: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION) 181
TABLE 129 FRANCE: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 181
10.3.4 UK 181
10.3.4.1 Rising number of hospitals and increasing government funding to drive market 181
TABLE 130 UK: KEY MACROINDICATORS 182
TABLE 131 UK: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION) 182
TABLE 132 UK: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION) 182
TABLE 133 UK: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION) 183
TABLE 134 UK: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION) 183
TABLE 135 UK: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION) 183
TABLE 136 UK: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION) 184
TABLE 137 UK: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION) 184
TABLE 138 UK: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION) 185
TABLE 139 UK: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 185
10.3.5 ITALY 185
10.3.5.1 Unfavorable reforms and reduction in healthcare expenditure by government to limit market 185
TABLE 140 ITALY: KEY MACROINDICATORS 186
TABLE 141 ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION) 186
TABLE 142 ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION) 187
TABLE 143 ITALY: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION) 187
TABLE 144 ITALY: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION) 187
TABLE 145 ITALY: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION) 188
TABLE 146 ITALY: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION) 188
TABLE 147 ITALY: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION) 189
TABLE 148 ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION) 189
TABLE 149 ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 189
10.3.6 SPAIN 190
10.3.6.1 Increasing healthcare spending and growing demand for home care services to drive market 190
TABLE 150 SPAIN: KEY MACROINDICATORS 190
TABLE 151 SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION) 191
TABLE 152 SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION) 191
TABLE 153 SPAIN: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION) 191
TABLE 154 SPAIN: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION) 192
TABLE 155 SPAIN: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION) 192
TABLE 156 SPAIN: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION) 192
TABLE 157 SPAIN: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION) 193
TABLE 158 SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION) 193
TABLE 159 SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 194
10.3.7 REST OF EUROPE 194
TABLE 160 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION) 194
TABLE 161 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION) 195
TABLE 162 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION) 195
TABLE 163 REST OF EUROPE: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION) 195
TABLE 164 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION) 196
TABLE 165 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION) 196
TABLE 166 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION) 197
TABLE 167 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION) 197
TABLE 168 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 198

10.4 ASIA PACIFIC 198
FIGURE 37 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET SNAPSHOT 199
TABLE 169 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 200
TABLE 170 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION) 200
TABLE 171 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION) 200
TABLE 172 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION) 201
TABLE 173 ASIA PACIFIC: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION) 201
TABLE 174 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION) 201
TABLE 175 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION) 202
TABLE 176 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION) 202
TABLE 177 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION) 203
TABLE 178 ASIA PACIFIC RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 203
10.4.1 ASIA PACIFIC: RECESSION IMPACT 203
10.4.2 JAPAN 204
10.4.2.1 Availability of universal healthcare reimbursement policy and growth in geriatric population to drive market 204
TABLE 179 JAPAN: KEY MACROINDICATORS 204
TABLE 180 JAPAN: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION) 205
TABLE 181 JAPAN: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION) 205
TABLE 182 JAPAN: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION) 205
TABLE 183 JAPAN: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION) 206
TABLE 184 JAPAN: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION) 206
TABLE 185 JAPAN: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION) 206
TABLE 186 JAPAN: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION) 207
TABLE 187 JAPAN: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION) 207
TABLE 188 JAPAN RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 207
10.4.3 CHINA 208
10.4.3.1 Modern healthcare systems and improved reimbursement policies to drive market 208
TABLE 189 CHINA: KEY MACROINDICATORS 208
TABLE 190 CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION) 209
TABLE 191 CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION) 209
TABLE 192 CHINA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION) 209
TABLE 193 CHINA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION) 210
TABLE 194 CHINA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION) 210
TABLE 195 CHINA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION) 210
TABLE 196 CHINA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION) 211
TABLE 197 CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION) 211
TABLE 198 CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 212
10.4.4 INDIA 212
10.4.4.1 Large patient population and availability of skilled medical professionals to drive market 212
TABLE 199 INDIA: KEY MACROINDICATORS 212
TABLE 200 INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION) 213
TABLE 201 INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION) 213
TABLE 202 INDIA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION) 213
TABLE 203 INDIA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION) 214
TABLE 204 INDIA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION) 214
TABLE 205 INDIA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION) 214
TABLE 206 INDIA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION) 215
TABLE 207 INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION) 215
TABLE 208 INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 216
10.4.5 AUSTRALIA 216
10.4.5.1 Growing prevalence of chronic lung diseases to drive market 216
TABLE 209 AUSTRALIA: KEY MACROINDICATORS 216
TABLE 210 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION) 217
TABLE 211 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION) 217
TABLE 212 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION) 217
TABLE 213 AUSTRALIA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION) 218
TABLE 214 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION) 218
TABLE 215 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION) 218
TABLE 216 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION) 219
TABLE 217 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION) 219
TABLE 218 AUSTRALIA RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 220
10.4.6 SOUTH KOREA 220
10.4.6.1 Increasing geriatric population and rising disposable income to drive market 220
TABLE 219 SOUTH KOREA: KEY MACROINDICATORS 220
TABLE 220 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION) 221
TABLE 221 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION) 221
TABLE 222 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION) 221
TABLE 223 SOUTH KOREA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION) 222
TABLE 224 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION) 222
TABLE 225 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION) 222
TABLE 226 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION) 223
TABLE 227 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION) 223
TABLE 228 SOUTH KOREA RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 224
10.4.7 REST OF ASIA PACIFIC 224
TABLE 229 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION) 224
TABLE 230 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION) 225
TABLE 231 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION) 225
TABLE 232 REST OF ASIA PACIFIC: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION) 225
TABLE 233 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION) 226
TABLE 234 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION) 226
TABLE 235 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION) 227
TABLE 236 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION) 227
TABLE 237 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 228
10.5 LATIN AMERICA 228
TABLE 238 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 228
TABLE 239 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION) 229
TABLE 240 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION) 229
TABLE 241 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION) 229
TABLE 242 LATIN AMERICA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION) 230
TABLE 243 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION) 230
TABLE 244 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION) 230
TABLE 245 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION) 231
TABLE 246 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION) 231
TABLE 247 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 232
10.5.1 LATIN AMERICA: RECESSION IMPACT 232
10.5.2 BRAZIL 232
10.5.2.1 Favorable healthcare initiatives by government to drive market 232
TABLE 248 BRAZIL: KEY MACROINDICATORS 233
TABLE 249 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION) 233
TABLE 250 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION) 233
TABLE 251 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION) 234
TABLE 252 BRAZIL: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION) 234
TABLE 253 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION) 234
TABLE 254 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION) 235
TABLE 255 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION) 235
TABLE 256 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION) 236
TABLE 257 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 236
10.5.3 MEXICO 236
10.5.3.1 Rising obesity rates and improving medical tourism to drive market 236
TABLE 258 MEXICO: KEY MACROINDICATORS 237
TABLE 259 MEXICO: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION) 237
TABLE 260 MEXICO: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION) 237
TABLE 261 MEXICO: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION) 238
TABLE 262 MEXICO: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION) 238
TABLE 263 MEXICO: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION) 238
TABLE 264 MEXICO: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION) 239
TABLE 265 MEXICO: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION) 239
TABLE 266 MEXICO: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION) 240
TABLE 267 MEXICO: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 240
10.5.4 REST OF LATIN AMERICA 240
TABLE 268 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION) 241
TABLE 269 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION) 241
TABLE 270 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION) 241
TABLE 271 REST OF LATIN AMERICA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION) 242
TABLE 272 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION) 242
TABLE 273 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION) 242
TABLE 274 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION) 243
TABLE 275 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION) 243
TABLE 276 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 244
10.6 MIDDLE EAST & AFRICA 244
10.6.1 GROWING PATIENT POPULATION AND INCREASING PENETRATION OF PRIVATE HEALTH INSURANCE COMPANIES TO DRIVE MARKET 244
TABLE 277 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION) 245
TABLE 278 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION) 245
TABLE 279 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION) 245
TABLE 280 MIDDLE EAST & AFRICA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION) 246
TABLE 281 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION) 246
TABLE 282 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION) 246
TABLE 283 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION) 247
TABLE 284 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION) 247
TABLE 285 MIDDLE EAST & AFRICA RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 248
10.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 248
11 COMPETITIVE LANDSCAPE 249
11.1 OVERVIEW 249
11.2 KEY STRATEGIES/RIGHT TO WIN 249
TABLE 286 KEY STRATEGIES ADOPTED BY MAJOR PLAYERS IN RESPIRATORY DIAGNOSTICS MARKET 250
11.3 REVENUE SHARE ANALYSIS 251
FIGURE 38 RESPIRATORY DIAGNOSTICS REVENUE SHARE ANALYSIS FOR MECHANICAL, TRADITIONAL, AND MOLECULAR TESTS, BY KEY PLAYER, 2018–2022 (USD MILLION) 251
FIGURE 39 RESPIRATORY DIAGNOSTICS REVENUE SHARE ANALYSIS FOR IMAGING TESTS, BY KEY PLAYER, 2018–2022 (USD MILLION) 252
11.4 MARKET SHARE ANALYSIS 252
FIGURE 40 RESPIRATORY DIAGNOSTICS MARKET SHARE FOR MECHANICAL, TRADITIONAL, AND MOLECULAR TESTS, BY KEY PLAYER, 2022 252
FIGURE 41 RESPIRATORY DIAGNOSTICS MARKET SHARE ANALYSIS FOR IMAGING TESTS, BY KEY PLAYER, 2022 253
11.5 COMPANY EVALUATION MATRIX 253
11.5.1 STARS 253
11.5.2 EMERGING LEADERS 253
11.5.3 PERVASIVE PLAYERS 254
11.5.4 PARTICIPANTS 254
FIGURE 42 COMPANY EVALUATION MATRIX, 2022 254
11.5.5 COMPANY FOOTPRINT 255
TABLE 287 PRODUCT AND SERVICE FOOTPRINT 255
TABLE 288 TEST TYPE FOOTPRINT 256
TABLE 289 END USER FOOTPRINT 257
TABLE 290 REGIONAL FOOTPRINT 258
TABLE 291 OVERALL COMPANY FOOTPRINT 259
11.6 START-UP/SME EVALUATION MATRIX 260
11.6.1 PROGRESSIVE COMPANIES 260
11.6.2 RESPONSIVE COMPANIES 260
11.6.3 DYNAMIC COMPANIES 260
11.6.4 STARTING BLOCKS 260
FIGURE 43 START-UP/SME EVALUATION MATRIX, 2022 261
11.6.5 COMPETITIVE BENCHMARKING 262
11.7 COMPETITIVE SCENARIOS AND TRENDS 263
11.7.1 KEY PRODUCT LAUNCHES 263
TABLE 292 KEY PRODUCT LAUNCHES, 2021–2023 263
11.7.2 KEY DEALS 264
TABLE 293 KEY DEALS, 2021–2023 264
11.7.3 OTHER KEY DEVELOPMENTS 265
TABLE 294 OTHER KEY DEVELOPMENTS, 2021–2023 265
12 COMPANY PROFILES 266
12.1 KEY PLAYERS 266
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
12.1.1 KONINKLIJKE PHILIPS N.V. 266
TABLE 295 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW 266
FIGURE 44 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2022) 267
12.1.2 BECTON, DICKINSON AND COMPANY 272
TABLE 296 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW 272
FIGURE 45 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022) 273
12.1.3 ABBOTT 277
TABLE 297 ABBOTT: COMPANY OVERVIEW 277
FIGURE 46 ABBOTT: COMPANY SNAPSHOT (2022) 278
12.1.4 THERMO FISHER SCIENTIFIC INC. 280
TABLE 298 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 280
FIGURE 47 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022) 281
12.1.5 GE HEALTHCARE 285
TABLE 299 GE HEALTHCARE: COMPANY OVERVIEW 285
FIGURE 48 GE HEALTHCARE: COMPANY SNAPSHOT (2022) 286
12.1.6 BIO-RAD LABORATORIES, INC. 293
TABLE 300 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 293
FIGURE 49 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022) 294
12.1.7 BIOMÉRIEUX 298
TABLE 301 BIOMÉRIEUX: COMPANY OVERVIEW 298
FIGURE 50 BIOMÉRIEUX: COMPANY SNAPSHOT (2022) 299
12.1.8 REVVITY, INC. 301
TABLE 302 REVVITY, INC.: COMPANY OVERVIEW 301
FIGURE 51 PERKINELMER INC.: COMPANY SNAPSHOT (2022) 302
12.1.9 SEEGENE INC. 305
TABLE 303 SEEGENE INC.: COMPANY OVERVIEW 305
FIGURE 52 SEEGENE INC.: COMPANY SNAPSHOT (2022) 305
12.1.10 NIHON KOHDEN CORPORATION 310
TABLE 304 NIHON KOHDEN CORPORATION: COMPANY OVERVIEW 310
FIGURE 53 NIHON KOHDEN CORPORATION: COMPANY SNAPSHOT (2022) 311
12.1.11 VITALOGRAPH 313
TABLE 305 VITALOGRAPH: COMPANY OVERVIEW 313
12.1.12 SDI DIAGNOSTICS 315
TABLE 306 SDI DIAGNOSTICS: COMPANY OVERVIEW 315
12.1.13 RESMED 317
TABLE 307 RESMED: COMPANY OVERVIEW 317
FIGURE 54 RESMED: COMPANY SNAPSHOT (2022) 318
12.1.14 SIEMENS HEALTHCARE GMBH 320
TABLE 308 SIEMENS HEALTHCARE GMBH: COMPANY OVERVIEW 320
FIGURE 55 SIEMENS HEALTHCARE GMBH: COMPANY SNAPSHOT (2022) 320
12.1.15 COSMED SRL 325
TABLE 309 COSMED SRL: COMPANY OVERVIEW 325
12.1.16 HOLOGIC, INC. 327
TABLE 310 HOLOGIC, INC.: COMPANY OVERVIEW 327
FIGURE 56 HOLOGIC, INC.: COMPANY SNAPSHOT (2022) 328
12.1.17 QIAGEN 331
TABLE 311 QIAGEN: COMPANY OVERVIEW 331
FIGURE 57 QIAGEN: COMPANY SNAPSHOT (2022) 331
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
12.2 OTHER PLAYERS 336
12.2.1 VYAIRE MEDICAL, INC. 336
12.2.2 VISBY MEDICAL, INC. 337
12.2.3 BRIOTA TECHNOLOGIES PVT. LTD. 337
12.2.4 BIRD HEALTHCARE 338
12.2.5 LÖWENSTEIN MEDICAL TECHNOLOGY GMBH 339
12.2.6 PROAXSIS 339
12.2.7 NDD MEDICAL TECHNOLOGIES 340
12.2.8 COMPUMEDICS LIMITED 341
13 APPENDIX 342
13.1 DISCUSSION GUIDE 342
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 347
13.3 CUSTOMIZATION OPTIONS 349
13.4 RELATED REPORTS 349
13.5 AUTHOR DETAILS 350

※본 조사보고서 [글로벌 호흡기 진단 시장 예측 (~2029) :기기, 시약, 소프트웨어] (코드 : MD4740-23) 판매에 관한 면책사항을 반드시 확인하세요.

※본 조사보고서 [글로벌 호흡기 진단 시장 예측 (~2029) :기기, 시약, 소프트웨어] 에 대해서 E메일 문의는 여기를 클릭하세요.

※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요!

[이하, 관련 보고서 소개]

세계의 광음향 이미징 시장 (~2029) : 이미징 시스템, 트랜스듀서, 소프트웨어, 부속품
MD9059 / MarketsandMarkets / 2024년 7월 / ...“글로벌 광음향 이미징 시장은 2024년 8천만 달러에서 2029년 1억 5천만 달러에 달할 것으로 예상되며, 2024년부터 2029년까지 예측 기간 동안 5.5%의 연평균 성장률을 기록할 것으로 전망됩니다.” 이 시장은 전임상 및 임상 연구 활동의 증가와 효율성을 높이는 기술 발전으로 인해 상승 추세를 보이고 있습니다. 하지만 숙련된 인력 부족과 광음향 이미징 구현에 드는...

세계의 크리에이티브 소프트웨어 시장 2024-2030 : 사운드 및 비디오 레코딩 소프트웨어, 이미지 및 비디오 편집 소프트웨어, 그래픽 및 일러스트레이션 소프트웨어, 탁상 출판 소프트웨어
GRV24MAY111 / Grand View Research / 2024년 4월 / 글로벌 크리에이티브 소프트웨어 시장의 성장과 동향 Grand View Research, Inc.사의 최신 보고서에 따르면, 세계의 크리에이티브 소프트웨어 시장 규모는 2030년까지 149억 8천만 달러에 달할 것으로 예상되며, 2024년부터 2030년까지 연평균 7. 1%의...1. 조사 방법 및 범위 2. 개요 3. 시장 변수, 동향, 범위 4. 크리에이티브 소프트웨어 시장 전개 예측 및 동향 분석 5. 크리에이티브 소프트웨어 시장 유형별 예측 및 동향 분석 6. 크리에이티브 소프트웨어 시장 지역별 예측 및 동향 분석 7. 경쟁 현황...

세계의 동물용 영상 진단 시장 (~2029년) : 제품별 (초음파 (2D, 3D, 도플러), CT, 엑스레이, MRI, 조영제, 소프트웨어), 양식별 (고정식, 휴대용), 용도별 (정형외과, 산부인과, 암), 동물별 (소동물, 대동물), 최종 용도별 (진료소, 병원)
MD3711-24 / MarketsandMarkets / 2023년 12월 / "글로벌 동물용 영상 진단 시장은 2023년 약 19억 달러로 추정되며, 예측 기간 동안 7.2%의 CAGR로 2029년까지 29억 달러에 달할 것으로 예상됩니다." 주요 트렌드는 더 빠른 진단을 위한 AI 기반 이미지...1. 서론 2. 조사 방법 3. 개요 4. 프리미엄 인사이트 5. 시장 개요 6. 세계의 동물용 영상 진단 시장 규모 : 제품별 7. 세계의 동물용 영상 진단 시장 규모 : 양식별 8. 세계의 동물용 영상 진단 시장 규모 : 용도별 9. 세계의 동물용 영상 진단 시장 규모 : 동물 종류별...

세계의 단백질 발현 시장 (~2029) : 시약, 벡터, 유능한 세포, 장치, 소프트웨어
BT 2435 / MarketsandMarkets / 2024년 11월 / ...“세계 단백질 발현 시장은 2029년에 48.2억 달러에 이를 것으로 예상되며, 2024년에는 34.1억 달러에서 예측 기간 중 CAGR은 7.1%” 제약 및 바이오 의약품 업계의 연구개발 활동 증가에 힘입은 생물 제제의 수요 증가와 단백질 기반 연구를 강화하기 위한 인공지능 및 기계 학습의 이용 확대와 같은 요인이 시장 성장을 뒷받침하고 있습니다. 또한 개별화...

세계의 유전자 편집 시장 (~2029) : 키트, 시약, 라이브러리, 소프트웨어
BT 3380 / MarketsandMarkets / 2024년 11월 / ...“유전자 편집 시장은 2024년 46.6억 달러에서 2029년에는 75.9억 달러에 이를 것으로 예상되며, 예측 기간 중 CAGR은 10.2%” 유전자 편집 기술의 발전, 유전자 편집 응용 범위 확대 등의 요인이 유전자 편집 시장의 성장을 촉진하고 있습니다. 그러나 시장은 유전자 편집의 오프타겟 효과로 인한 몇 가지 문제에 직면해 있으며, 확장성 및 제조의 어려움과...